RESUMEN
The aim of the present study was to evaluate ischaemic reactive hyperaemia (IRH) in obstructive sleep apnoea (OSA) and its relationship with oxidative stress. We studied 69 consecutive patients referred to our Sleep Unit (Reina Sofia University Hospital, Cordoba, Spain). Patients with chronic diseases or those taking medication were excluded. IRH was assessed before and after polysomnography. Morning IRH and oxidative stress markers were compared between patients with (apnoea-hypopnoea index (AHI) ≥ 5) and without (AHI < 5) OSA. Measurements were repeated in 25 severe OSA patients after continuous positive airway pressure (CPAP) therapy. We included 46 OSA patients (mean ± sd AHI 49 ± 32.1) and 23 non-OSA subjects (AHI 3 ± 0.9). The OSA patients showed a significant worsening of morning IRH, and a significant increase in malondialdehyde and 8-hydroxydeoxyguanosine levels. Only the oxygen desaturation index independently explained morning IRH, while malondialdehyde levels showed a weak effect on IRH. In severe OSA patients, IRH improved significantly after CPAP treatment, as did malondialdehyde, 8-hydroxydeoxyguanosine and protein carbonyl levels. In OSA patients, endothelial dysfunction and oxidative stress were observed, and IRH worsened after sleep. The increase in oxidative stress was not associated with IRH, while intermittent hypoxia was strongly associated with IRH. In severe OSA patients, CPAP treatment improved oxidative stress and endothelial function.
Asunto(s)
Endotelio/metabolismo , Regulación de la Expresión Génica , Estrés Oxidativo , Apnea Obstructiva del Sueño/metabolismo , 8-Hidroxi-2'-Desoxicoguanosina , Adulto , Desoxiguanosina/análogos & derivados , Desoxiguanosina/metabolismo , Endotelio Vascular/metabolismo , Femenino , Humanos , Hipoxia/metabolismo , Masculino , Malondialdehído/metabolismo , Persona de Mediana Edad , Oxígeno/química , Polisomnografía/métodos , Estudios ProspectivosRESUMEN
OBJECTIVE: To determine quantitative and qualitative differences of aqueous humor proteome in patients with and without glaucoma. METHOD: Observational, descriptive and cross-sectional study of 12 patients (8 men; 4 women) with and without glaucoma. There are 3 groups of minority proteins with serum equimolar contribution of each of the patients. Specimens were obtained during cataract surgery from patients without glaucoma (performed with retrobulbar anaesthesia [cataract retrobulbar patient -CRP-;n=4] or topical [cataract topical patient -CTP-; n=4]), or from patients with glaucoma (performed with retrobulbar anaesthesia [glaucoma retrobulbar patient -GRP-; n=4]). The humor proteome samples were frozen at -80°C until processing by trypsin digestion to obtain tryptic peptides, and then performing liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) to obtain the proteome and its differential expression between groups. Statistical analysis was performed using the SPSS v.17 program. RESULTS: The study included 12 patients, aged (mean±standard deviation) 74.50±9.53 years. Concentrations obtained: 0.48±0.25µg/µl for CRP, 0.28±0.04µg/µl for CTP, and 0.35±0.16µg/µl for GRP. A total of 309 proteins were identified, of which 205, 210, and 182 were in CRP, CTP, and GRP, respectively. A total of 114 proteins were common to all three groups, 50 were exclusive to CRP, 58 to CTP, and 27 to GRP. CONCLUSIONS: In this pilot study, a quantitative difference was found in the protein expression of humor among patients with glaucoma, there being 27 proteins unique to patients with glaucomatous disease.
Asunto(s)
Humor Acuoso/metabolismo , Glaucoma/metabolismo , Proteoma/biosíntesis , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proyectos PilotoRESUMEN
The data are related to the proteomic analysis of 43 newborns with intrauterine growth retardation (IUGR) and 45 newborns with appropriate weight for gestational age (AGA) carried out by separation via 2DE and analyzed by MS-TOF/TOF. All newborns were separated into three gestational age groups, "Very Preterm" 29-32 weeks, "Moderate Preterm" 33-36 weeks, and, "Term" ≥37weeks. From each newborn, blood was drawn three times from birth to 1 month life. High-abundant serum proteins were depleted, and the minority ones were separated by 2DE and analyzed for significant expression differences. The data reflect analytic and clinic variables analyzed globally and categorized by gestational age in relation to IUGR and the optimization of conditions for 2-DE separation. The data from this study are related to the research article entitled "Alterations of Protein Expression in Serum of Infants with Intrauterine Growth Restriction and Different Gestational Ages" (M.D. Ruis-González, M.D. Cañete, J.L. Gómez-Chaparro, N. Abril, R. Cañete, J. López-Barea, 2015) [1]. The present dataset of serum IUGR newborn proteome can be used as a reference for any study involving intrauterine growth restriction during the first month of life.
RESUMEN
Objetivo: Se diseña un estudio con el objetivo de valorar el papel de la proteómica en la identificación de proteínas diferenciales en pacientes con SAHS. Pacientes y métodos: Fueron incluidos 37 enfermos con sintomatología sugestiva de SAHS y un IAH ≥ 5 y un grupo control compuesto por 18 sujetos roncadores, emparejados por IMC, género y edad con el grupo con SAHS en los que se descartó un SAHS (IAH < 5). En ambos grupos se excluyeron a los sujetos que estaban diagnosticados de enfermedad crónica avanzada. En primer lugar se efectuó electroforesis bidimensional que comparó los geles de ambos grupos y estableció los spots diferenciales (sobreexpresión > 2,5 veces el grupo control y subexpresión < 0,5 veces por debajo del grupo control). Posteriormente se realizó espectrometría de masas mediante MALDI /TOF-TOF (matrix laser assisted desorption- time of flight).Resultados: Respecto al grupo control, IAH = 3,5 (3-4,1), en los enfermos con SAHS, IAH = 53 (27-74), mediante MALDI/TOF-TOF se identificó una proteína sobreexpresada, la haptoglobina que se ha relacionado con mayor riesgo vascular en pacientes con SAHS. Igualmente se identificaron dos proteínas subexpresadas, la albúmina y serotransferrina, proteínas que pueden facilitar una disminución de las defensas antioxidantes en el SAHS. Conclusiones: Se aporta el primer perfil proteómico diferencial en pacientes adultos con SAHS. Se demuestra la validez de la proteómica para identificar un conjunto de proteínas diferenciales que puedan ser útiles para el diagnóstico o para establecer un perfil de riesgo vascular (AU)
Objective: a study was designed to assess the role of proteomics in the identification of differential proteins in patient with obstructive sleep apnea-hypopnea syndrome (OSAH). Patients and methods: Thirty seven patients with symptoms suggestive of OSAH and a apnea-hypopnea index (AHI) ≥ 5 were included in the study, and a control group was made up of 18 snorers, matched for BMI, gender and age with the OSAH group in which one OSAH was discarded (AHI < 5). Subjects diagnosed with advanced chronic disease were excluded from both groups. First, two-dimensional electrophoresis was performed, which compared the gels of both groups and established the differential spots (over-expression > 2.5 times the control group and under-expression < 0.5 times below the control group). Subsequently, a mass spectrometry was performed by means of MALDI / TOF-TOF (matrix laser assisted desorption - time of flight). Results: Regarding the control group, mean AHI = was 3.5 (3-4.1), and in those affected with OSAH it was, AHI = 53 (27-74). , Aan over-expressed protein, haptoglobin, was identified by means of MALDI/TOF-TOF, which has been related with a greater vascular risk in patient with OSAH. Likewise, two under-expressed proteins, albumin and serotransferrin, were identified, proteins that can facilitate a decrease of the anti-oxidant defences in OSAH. Conclusions: An initial differential proteomic profile in mature patients with OSAH was found. The legitimacy of proteomics to identify a group of differential proteins that could be useful to diagnosis or establish a profile of vascular risk has been demonstrated (AU)